Home / Science / Dog Aging Pill Nears FDA Approval
Dog Aging Pill Nears FDA Approval
17 Oct
Summary
- A new daily pill targets aging in dogs by reducing a specific hormone.
- The drug, LOY-002, has cleared a major regulatory hurdle for FDA approval.
- This innovation could potentially extend healthy lifespans for dogs.
A biotech company named Loyal is developing a daily pill, LOY-002, aimed at slowing the aging process in dogs. The drug has recently cleared a significant regulatory step, with the FDA reviewing its potential efficacy.
LOY-002 works by reducing levels of insulin-like growth factor 1 (IGF-1), a hormone associated with faster cellular aging, particularly in larger breeds. This approach seeks to slow a dog's biological clock, thereby lowering the risk of age-related diseases and preserving a higher quality of life in their senior years.
The prescription pill is intended for dogs aged 10 and older, weighing over 14 pounds. Loyal's ongoing STAY study, a large-scale clinical trial involving 1,300 dogs, is contributing to the FDA's review process.
The FDA has already approved the Target Animal Safety portion of the application. Combined with the finding that LOY-002 is likely effective, the company is on track for conditional approval, with the manufacturing submission expected in 2027. This means the drug could be available to veterinarians as early as next year.
This research also holds implications for human longevity studies, as dogs share many biological similarities and age at an accelerated rate, allowing for quicker testing of aging treatments.
